F. Moureau

601 total citations
17 papers, 512 citations indexed

About

F. Moureau is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, F. Moureau has authored 17 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Cellular and Molecular Neuroscience and 5 papers in Organic Chemistry. Recurrent topics in F. Moureau's work include Lanthanide and Transition Metal Complexes (4 papers), Chemical Synthesis and Analysis (3 papers) and Neuroscience and Neuropharmacology Research (3 papers). F. Moureau is often cited by papers focused on Lanthanide and Transition Metal Complexes (4 papers), Chemical Synthesis and Analysis (3 papers) and Neuroscience and Neuropharmacology Research (3 papers). F. Moureau collaborates with scholars based in Belgium, France and Switzerland. F. Moureau's co-authors include F. Durant, Johan Wouters, G. Evrard, Philippe Michel, Bénédicte Lallemand, Benoît Kenda, Michel Gillard, Edmond Differding, Patrick Pasau and Alain Matagne and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry.

In The Last Decade

F. Moureau

16 papers receiving 501 citations

Peers

Countries citing papers authored by F. Moureau

Since Specialization

Citations

This map shows the geographic impact of F. Moureau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Moureau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Moureau more than expected).

Fields of papers citing papers by F. Moureau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Moureau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Moureau. The network helps show where F. Moureau may publish in the future.

Co-authorship network of co-authors of F. Moureau

This figure shows the co-authorship network connecting the top 25 collaborators of F. Moureau. A scholar is included among the top collaborators of F. Moureau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Moureau. F. Moureau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O -Methyltransferase 2018 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Gregory V. Carr, (unknown), Michael DePasquale, (unknown), Yifang Huang, Martha Kimos, (unknown), Michael S. Poslusney, Huijun Wei, Dominique Swinnen, Florian Montel, F. Moureau, Émilie Jigorel, (unknown), Martyn Wood, James C. Barrow	14
2	Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands 2014 ·ChemMedChem ·Joël Mercier, (unknown), (unknown), Stéphane Carré, (unknown), Eric Jnoff, Benoît Kenda, Bénédicte Lallemand, Philippe Michel, Florian Montel, F. Moureau, (unknown), (unknown), Xavier Sauvage, Anne Valade, Laurent Provins	52
3	Discovery of orally bioavailable NK1 receptor antagonists 2003 ·Bioorganic & Medicinal Chemistry Letters ·Christophe Génicot, B. Christophe, Philippe Collart, Michel Gillard, Laurence Goossens, Jean‐Pierre Hénichart, (unknown), F. Moureau, (unknown), Jean‐Marie Nicolas, Patrick Pasau, Luc Quéré, Thomas Ryckmans, (unknown), Thierry Taverne, (unknown)	6
4	Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity 2003 ·Journal of Medicinal Chemistry ·Benoît Kenda, Alain Matagne, Patrice Talaga, Patrick Pasau, Edmond Differding, Bénédicte Lallemand, (unknown), F. Moureau, Henrik Klitgaard, Michel Gillard, B. B. Fuks, Philippe Michel	202
5	A reversible monoamine oxidase a inhibitor, befloxatone: structural approach of its mechanism of action 1999 ·Bioorganic & Medicinal Chemistry ·Johan Wouters, F. Moureau, G. Evrard, (unknown), Samir Jegham, Pascal George, F. Durant	72
6	Conformational analysis of pseudo-peptides: The case of FK888, a potent and selective substance P receptor antagonist 1998 ·Letters in Peptide Science ·F. Moureau, (unknown), (unknown), Solo Goldstein, R. Massingham	2
7	1998 ·Letters in Peptide Science ·F. Moureau, (unknown), (unknown), Solo Goldstein, R. Massingham	2
8	Bioactive conformations of peptides and mimetics as milestones in drug design: Investigation of NK1 receptor antagonists 1995 ·Letters in Peptide Science ·Solo Goldstein, (unknown), F. Moureau, (unknown), (unknown), Edmond Differding, Raymond Houssin, (unknown)	5
9	Stereoelectronic requirements of benzamide 5HT3 antagonists. Comparison with D2 antidopaminergic analogues 1995 ·Journal of the Chemical Society Perkin Transactions 2 ·Sonia Collin, F. Moureau, (unknown), Daniel P. Vercauteren, G. Evrard, (unknown)	9
10	A reversible monoamine oxidase inhibitor, Toloxatone: comparison of its physicochemical properties with those of other inhibitors including Brofaromine, Harmine, R40519 and Moclobemide 1995 ·European Journal of Medicinal Chemistry ·F. Moureau, Johan Wouters, (unknown), Daniel P. Vercauteren, F. Durant, (unknown), (unknown), (unknown)	24
11	Experimental and theoretical study of reversible monoamine oxidase inhibitors: structural approach of the active site of the enzyme 1994 ·PubMed ·Johan Wouters, F. Moureau, Daniel P. Vercauteren, G. Evrard, F. Durant, (unknown), (unknown), (unknown)	3
12	A reversible monoamine oxidase inhibitor, toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD) 1994 ·European Journal of Medicinal Chemistry ·F. Moureau, Johan Wouters, (unknown), Sonia Collin, G. Evrard, F. Durant, (unknown), (unknown), (unknown)	44
13	Structural characterization of oxidized lumiflavin hydrochloride hydrate: Comparison with the hydrogen bonding at the cofactor of flavoproteins 1994 ·Journal of Chemical Crystallography ·Johan Wouters, F. Moureau, (unknown), Bernadette Norberg, G. Evrard, F. Durant	5
14	Molecular Structure Analysis of Moclobemide, a Monoamine Oxidase Inhibitor 1993 ·Bulletin des Sociétés Chimiques Belges ·Johan Wouters, F. Moureau, Bernadette Norberg, G. Evrard, F. Durant	0
15	BEFLOXATONE, A SPONTANEOUSLY REVERSIBLE MAO-A INHIBITOR: MODELISATION AT MOLECULAR LEVEL 1992 ·Clinical Neuropharmacology ·(unknown), F. Moureau, Daniel P. Vercauteren, F. Durant, (unknown), (unknown)	3
16	A reversible monoamine oxidase inhibitor, toloxatone: Structural and electronic properties 1992 ·European Journal of Medicinal Chemistry ·F. Moureau, Johan Wouters, (unknown), Sonia Collin, G. Evrard, F. Durant, (unknown), (unknown), (unknown)	52
17	QSAR of nortropane-substituted benzamides: use of lipophilic (RP-HPLC) and electronic (1H NMR) parameters 1989 ·European Journal of Medicinal Chemistry ·Sonia Collin, Nabil El Tayar, H. Van De Waterbeemd, F. Moureau, Daniel P. Vercauteren, F. Durant, Michel Langlois, Bernard Testa	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact